Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” ...

The approval and availability of Epioxa, a noninvasive, epithelium-on, oxygen-enriched treatment for keratoconus represents a ...

Learning to adapt to life with geographic atrophy (GA), one woman finds new ways to stay true to her adventurous spirit ...

What is IZERVAY™?IZERVAY (avacincaptad pegol intravitreal solution) is a prescription eye injection, used to treat geographic atrophy (GA), the advanced form of dry age-related macular degeneration ...

"The AREDS2 formulation of oral micronutrient supplements slows down the progression of geographic atrophy towards the fovea in AMD. It does this by a large amount – as much as ~55% with the combined ...

Some foods have beneficial properties, whereas others can cause harm, especially where geographic atrophy (GA) is concerned. The dietary choices you make can accelerate the progression of this ...

Age is a major risk factor for geographic atrophy (GA). As the eyes age, natural defenses weaken, blood flow may decline, and waste removal may slow, allowing deposits called drusen to build up.

September 2, 2008 — A gene variant that protects against geographic atrophy has been identified by investigators from several institutions in China and the United States. The variant appears to ...

Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...